Human papillomavirus genotyping on Reunion Island: A cross-sectional study of stored tissue samples

被引:5
作者
Phuong Lien Tran [1 ]
Zafindraibe, Norosoa [2 ]
Ah-You, Nathalie [3 ]
Fernandez, Carla [3 ]
Arrivets, Pascaline [4 ]
Gerardin, Patrick [5 ]
Michault, Alain [2 ]
Boukerrou, Malik [1 ]
Bertolotti, Antoine [6 ,7 ]
机构
[1] Ctr Hosp Univ CHU La Reunion, Serv Gynecol & Obstet, St Pierre, La Reunion, France
[2] CHU La Reunion, Serv Microbiol, St Pierre, La Reunion, France
[3] CHU La Reunion, Serv Anat & Cytol Pathol, St Pierre, La Reunion, France
[4] Cabinet Anat & Cytol Pathol, St Pierre, La Reunion, France
[5] CHU La Reunion, INSERM, CIC 1410, St Pierre, La Reunion, France
[6] Antilles Univ, EA 4537, Guadeloupe, Martinique, France
[7] CHU La Reunion, Serv Malad Infect Dermatol, St Pierre, La Reunion, France
关键词
HPV; Genotype; Reunion Island; Vaccination; CERVICAL LESIONS; VACCINE; HPV; PREVALENCE; IMPACT; COVERAGE; LEVEL; WOMEN; RISK;
D O I
10.1016/j.ejogrb.2020.07.001
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: We aim to illustrate and evaluate the prevalence and distribution pattern of cervical human papilloma virus (HPV) genotypes on La Reunion Island, a French overseas territory, with the aim to guide future vaccination policies. Study design: Between January 2008 and July 2012, files of women undergoing gynaecological examination were retrospectively evaluated at the University Hospital, Reunion Island. Inclusion criteria required cervical biopsies with histopathological diagnosis of high-grade lesions or cancer and ASCUS Pap Smears (atypical squamous cells undetermined significance) results. The INNO-LIPA HPV Genotyping Extra (R) test was used for HPV genotyping. Results: A total of 401 ASCUS Pap Smears and 94 cervical biopsies were analyzed, of which 162 smears and 63 biopsies were HPV DNA positive (40.4 % and 67 % respectively). Detailed breakdowns of HPV genotype-specific distribution reported prevalence of HPV 16, 31, 33, 51 and 52. Of the 63 HPV-positive biopsies, 61 (96.8 %) contained at least one HPV genotype that is contained in the 9-valent HPV vaccine. The incremental preventable fraction of HPV infections that could have been added by the new 9-valent vaccine to the current bivalent vaccine was estimated at 26.2 %. Conclusions: Immunization with 9-valent vaccine should be effective, and in the long term, may reduce cervical cancer incidence in Reunion Island. Nevertheless, vaccination rates and coverage need to be maintained and improved. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:294 / 299
页数:6
相关论文
共 29 条
  • [1] [Anonymous], LANCET PUBLIC HLTH
  • [2] [Anonymous], 2020, GEODES SANTE PUBLIQU
  • [3] Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples
    Arreaza, Gladys
    Qiu, Ping
    Pang, Ling
    Albright, Andrew
    Hong, Lewis Z.
    Marton, Matthew J.
    Levitan, Diane
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (09):
  • [4] Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach
    Brotherton, Julia M. L.
    Murray, Sharron L.
    Hall, Madeline A.
    Andrewartha, Lynne K.
    Banks, Carolyn A.
    Meijer, Dennis
    Pitcher, Helen C.
    Scully, Megan M.
    Molchanoff, Luda
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2013, 199 (09) : 614 - 617
  • [5] Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis
    Bruni, Laia
    Diaz, Mireia
    Barrionuevo-Rosas, Leslie
    Herrero, Rolando
    Bray, Freddie
    Xavier Bosch, F.
    de Sanjose, Silvia
    Castellsague, Xavier
    [J]. LANCET GLOBAL HEALTH, 2016, 4 (07): : E453 - E463
  • [6] Bulletin de Veille Sanitaire, 2016, B VEILLE SANITAIRE C
  • [7] Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine
    Chao, C.
    Klein, N. P.
    Velicer, C. M.
    Sy, L. S.
    Slezak, J. M.
    Takhar, H.
    Ackerson, B.
    Cheetham, T. C.
    Hansen, J.
    Deosaransingh, K.
    Emery, M.
    Liaw, K. -L.
    Jacobsen, S. J.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2012, 271 (02) : 193 - 203
  • [8] Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer
    Chelimo, Carol
    Wouldes, Trecia A.
    Cameron, Linda D.
    Elwood, J. Mark
    [J]. JOURNAL OF INFECTION, 2013, 66 (03) : 207 - 217
  • [9] Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study
    Chow, Eric P. F.
    Danielewski, Jennifer A.
    Fehler, Glenda
    Tabrizi, Sepehr N.
    Law, Matthew G.
    Bradshaw, Catriona S.
    Garland, Suzanne M.
    Chen, Marcus Y.
    Fairley, Christopher K.
    [J]. LANCET INFECTIOUS DISEASES, 2015, 15 (11) : 1314 - 1323
  • [10] Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis
    Clifford, GM
    Smith, JS
    Aguado, T
    Franceschi, S
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (01) : 101 - 105